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Objective: To compare the Afﬁrm VPIII Microbial Identiﬁcation Test for detection and identiﬁcation of Candida
species, Gardnerella vaginalis and Trichomonas vaginalis to clinical and microscopic criteria commonly used to
diagnose vaginitis.
Methods: Women that were symptomatic for vaginitis/vaginosis and asymptomatic women being seen for
routine obstetric or gynecological care were included in this study. Women treated with antibiotics or
antifungals within one week or women who had douched within 24 hours were excluded. Two vaginal swab
specimens were simultaneously obtained from each patient, one swab was placed in sterile physiological saline
for immediate microscopic wet mount examination and KOH testing. The other swab was placed in the Afﬁrm
collection tube for Afﬁrm VPIII testing based on previously demonstrated methods.
Results: The Afﬁrm assay was signiﬁcantly more likely to identify Gardnerella and Candida than wet mount.
190 (45%) were positive for Gardnerella by Afﬁrm compared to 58 (14%) by wet mount; 45 (11%) were
positive for Candida by Afﬁrm compared to 31 (7%) by wet mount; and 30 (7%) were positive for
Trichomonas by Afﬁrm compared to 23 (5%) by wet mount. Symptomatic women were signiﬁcantly more
likely to be positive by Afﬁrm only (23% vs. 10%), wet mount only (3% vs. 2%) or Afﬁrm and wet mount
(15% vs. 1%). Asymptomatic women were signiﬁcantly more likely to be negative for Afﬁrm and wet mount
(43% vs. 5%).
Conclusions: The Afﬁrm VPIII test is a more sensitive diagnostic test for detection and identiﬁcation of
symptomatic vaginitis/vaginosis than conventional clinical examination and wet mount testing.
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INTRODUCTION
Vaginal discharge is one of the most common
women’s healthcare problems in the United
States
1. Infectious vaginitis is responsible for
between 5 and 10 million clinic visits annually
with related healthcare costs of over $500 million
each year
2. The three leading agents that cause
90% of infectious vaginitis are bacterial vaginosis
(BV); fungal infections (yeast); and parasitic
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common vaginal infection (causing 15–50% of all
vaginitis/vaginosis) and Gardnerella vaginalis is still
considered to be one of the major bacteria causing
this infection
3,4.
The clinical diagnosis of infectious vaginitis has
traditionally relied on tests performed at point of
care, such as a physical exam, the appearance of
vaginal discharge, a microscopic exam (wet
mount), a Potassium hydroxide (KOH) amine
odor test, and a pH test of vaginal ﬂuid, as well as
laboratory diagnosis via cultures and scored Gram
stains
5. Proper diagnosis and treatment can be
elusive if based on clinical symptoms and
character of the vaginal discharge alone. This
may lead to a lack of relief from symptoms and
may increase the costs to the patient from
inadequate or improper treatment
6.
In this study, we evaluated the Afﬁrm VPIII
Microbial Identiﬁcation Test (Becton Dickinson,
Sparks, MD, USA) for the detection and
identiﬁcation of Candida species, Gardnerella
vaginalis, and Trichomonas vaginalis from vaginal
ﬂuid specimens in both symptomatic and asymp-
tomatic patients. The Afﬁrm VPIII test was
compared to clinical criteria commonly used to
diagnose each syndrome as well as microscopic
results.
SUBJECTS AND METHODS
Study design
This study was conducted in Indianapolis, Indiana
at two clinical centers: Wishard Health Services (a
university-afﬁliated county hospital) and St.
Vincent Hospital (a suburban community hospi-
tal). Institutional Review Board approval was
obtained and veriﬁed by Becton Dickinson prior
to patient selection and specimen collection.
Patient selection and specimen collection
Symptomatic women were characterized for
inclusion in this study based on clinical ﬁndings
during examination and/or microscopic exam-
ination of the vaginal discharge. Asymptomatic
women were characterized for inclusion in this
study as those who lacked symptoms of vaginitis/
vaginosis and were being seen for routine
obstetric or gynecological exams. Women who
had received antibiotic or antifungal therapy
within the week or who had douched within
24 hours were excluded. The symptoms, sus-
pected diagnosis, and reason for the visit were
recorded and submitted with each specimen.
Clinical examination was performed to include
evaluation of vaginal discharge (if applicable).
Two vaginal swabs were obtained simultaneously
from patients. One swab was placed in sterile
physiological saline and immediately examined
microscopically for the presence of motile
trichomonads, clue cells, and/or yeast or hyphae.
A second drop was mixed with 10% KOH and
evaluated for the presence of amine odor. All
information from both the clinical and micro-
scopic assessments was recorded. The other swab
was placed in the Afﬁrm sample collection tube.
Sample testing
The Afﬁrm swab sample was transported to the
testing area within 1 hour at room temperature or
4 hours if refrigerated, and stored in the appro-
priate ambient temperature transport system
7.
The swab was then tested using the Afﬁrm VPIII
assay on the BD MicroProbe Processor according
to manufacturer’s recommendations. The Afﬁrm
VPIII test (Becton Dickinson and Company,
Sparks, MD, USA) is based on the principles of
nucleic acid hybridization and uses two distinct
single-stranded probes for each organism, a
capture probe and a color development probe.
After completion of the test, the results of the
assay were visually observed and the results were
recorded.
RESULTS
A total of 425 women were enrolled in this study.
One hundred and ninety patients (45%) were
positive for Gardnerella by Afﬁrm, while only 58
(14%) were positive by wet mount (clue cells
present). For Candida, 45 patients (11%) were
positive by the Afﬁrm and 31 (7%) were positive
by wet mount. For Trichomonas, 30 patients (7%)
were positive by Afﬁrm and 23 (5%) were
positive by wet mount (Table 1). Patients who
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were further categorized as symptomatic or
asymptomatic, as previously deﬁned (Table 2).
Symptomatic women were signiﬁcantly more
likely to be positive by Afﬁrm than asymptomatic
women (23% vs. 10%) and they were also more
likely to be positive by Afﬁrm and wet mount
(15% vs. 1%). For asymptomatic women, 43%
were negative for Afﬁrm and wet mount,
compared to 5% of symptomatic women.
Each patient was ultimately treated for vagini-
tis/vaginosis based on the results of the wet mount
and/or the Afﬁrm test. Patients with clinical signs
and symptoms of vaginitis/vaginosis and positive
wet mount or Afﬁrm test were treated with
appropriate therapy (metronidazole, ﬂuconazole
or terconazole). Patients with no symptoms of
vaginitis/vaginosis and a positive wet mount or
Afﬁrm test were also treated with appropriate
therapy. Five percent of the patients who reported
clinical symptoms but exhibited negative wet
mount and Afﬁrm test results, were not treated.
DISCUSSION
Sobel reports that three quarters of all adult
women experience at least one episode of
candidiasis during their lifetime, with approxi-
mately 5% suffering from recurrent infections
4.
Additionally, over 5 million new cases of
trichomoniasis are reported each year in the
USA alone, and up to 18 million new cases are
reported worldwide
2,8. Mixed infections are
common in up to 25% of patients with infectious
vaginitis. Furthermore, up to 50% of vaginal
infections are asymptomatic, or diagnosis may be
masked by menstruation or prior treatment with
over-the-counter creams or douching.
Previous studies have shown that traditional
tests for diagnosis and identiﬁcation of the
organism responsible for vaginitis/vaginosis often
lack sensitivity or are of little clinical utility. For
example, Gram stain diagnosis for BV has been
shown to have a sensitivity of 62–93% as
compared to clinical diagnosis
9–11, and cultures
for G.vaginalis are of questionable signiﬁcance
since up to 50% of women without BV may be
colonized with this organism
10–12. For tricho-
moniasis, microscopic demonstration of motile
trichomonads is the most common basis for
diagnosis. However, previous studies have re-
ported that wet mounts tend to be signiﬁcantly
less sensitive compared to other methods such as
culture and Pap smears
13,14. The Trichomonas
culture, which is considered the gold standard,
has improved sensitivity but lacks clinical utility
due to an extended turn-around time of up to 5
days.
Clinically, patients with BV or trichomoniasis
are at greater risk of becoming HIV positive
15,
and may experience increased pregnancy compli-
cations such as premature rupture of membranes,
preterm delivery and low birth weight
2. They
may also experience an increase in post-surgical
gynecological infections
16–18.
The Afﬁrm VPIII assay simultaneously detects
the presence of clinically signiﬁcant levels of
Table 1 Number of specimens positive for each organism for each test
Pathogen (n=425) AFFIRM VPIII Wet Mount T-statistic p-value
Trichomonas vaginalis 30 (7%) 23 (5%) 1.2 0.22
Gardnerella vaginalis 190 (45%) 58 (14%)* 10.5 0.00
Candida species 45 (11%) 31 (7%)** 2.0 0.04
*p=0.001, **p=0.04
Table 2 Patients positive for Gardnerella, Candida, and/or
Trichomonas versus the presence of symptoms for each test
system
Result and test system Symptomatic Asymptomatic
Positive Afﬁrm only 96 (23%) 42 (10%)**
Positive wet mount only 11 (3%) 8 (2%)*
Positive Afﬁrm and wet
mount
63 (15%) 4 (1%)**
Negative Afﬁrm and wet
mount
20 (5%) 181 (43%)**
*p 50.001, ** p 50.0001
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specimens
5,7. This easy to read test has a total
hands-on time of approximately 5 minutes, with
test results available in less than 1 hour. An
extended specimen transport option, Afﬁrm
VPIII Ambient Temperature Transport System
(ATTS), is also available which extends specimen
stability to 72 hours at ambient temperature
7.
Each of these test characteristics is important since
it was developed for use in the physician’s ofﬁce
as well as the clinical laboratory. Clinicians,
particularly in lower prevalence populations,
may have difﬁculty interpreting traditional point
of care testing for these pathogens. This phenom-
enon may account for the vast discrepancy in the
detection of G. vaginalis from Afﬁrm (45%) and
wet mount (14%) in this study.
It is also evident that clinicians rely heavily on
diagnostic tests to determine treatment. In this
study, 10% of the women positive for Gardnerella,
Candida, and/or Trichomonas would not have been
treated if clinicians relied on clinical symptoms
and wet mount results only. This is especially
important for women with BV as it is estimated
that up to 50% of these infections are asympto-
matic
2. These statistics are further complicated by
the risks involved for both mother and child, if
women with BV are pregnant. It has been
reported that up to 30% of pregnant women
have BV. Additionally, pregnant women with
Trichomonas and Gardnerella infections that are
misdiagnosed or not properly treated could
experience extreme consequences associated with
pre-term and low birth weight babies, which
incur greater medical costs and long-term costs in
child development. There are new speciﬁc
therapy options that would rely on a rapid and
accurate differential diagnosis
18,19. The need for
rapid, accurate and differential diagnosis is further
emphasized by the costs of treatment for other
risk factors associated with vaginal infections, such
as the acquisition and transmission of HIV, other
sexually transmitted diseases, as well as the
complications associated with pelvic inﬂamma-
tory disease (PID).
The Afﬁrm VPIII assay is an excellent
diagnostic test that will help to rapidly and
accurately diagnose vaginitis/vaginosis in both
point of care and clinical laboratory settings.
Furthermore, we have shown in previous studies
with the Afﬁrm test, that clinicians can collect
specimens, send them for immediate testing and/
or have the transport and test time delayed up to
72 hours with little or no decrease in sensitivity
7.
The Afﬁrm VPIII test is easy to perform and is less
cumbersome than traditional point of care tests
such as the wet mount test.
The results of this study show that the Afﬁrm
VPIII test is more sensitive in symptomatic
women than the conventional and more
cumbersome point of care wet mount test. As
such, we believe that the Afﬁrm’s rapid,
automated system can offer several advantages
in overcoming many diagnostic challenges in
certain situations, such as: (1) difﬁcult to
diagnose cases in women who frequently
douche, are menstruating, or have recently had
intercourse; (2) cases with mixed infections that
are rarely detected by microscopy; (3) women
with recurrent, chronic infections; (4) women
with other sexually transmitted diseases that
need accurate differentiation and treatment; and
(5) pregnant women at high-risk for poor
perinatal outcome.
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